Clinical Report: New Treatment for Thyroid Eye Disease Approved
Overview
The FDA has approved Lumvoa™ (veligrotug-vvze) for active and chronic thyroid eye disease (TED). The approval is based on the THRIVE clinical program, which demonstrated improvements in proptosis and diplopia.
Background
Thyroid eye disease (TED) presents treatment challenges due to its impact on patients' visual function and quality of life. Historically, treatment options have been limited, with few medical therapies showing efficacy. The approval of Lumvoa provides a new therapeutic option that targets the IGF-1 receptor.
Data Highlights
| Outcome Measure | Response Rate |
|---|---|
| Proptosis Reduction (>2 mm) | ~70% |
| Diplopia Improvement | ~60% |
| Hearing Symptoms | 5% (placebo adjusted) |
Key Findings
- Lumvoa is the first treatment to show statistically significant diplopia response and resolution in TED.
- Clinical trials indicated an average proptosis reduction of nearly 3 mm.
- Approximately 70% of patients experienced a reduction in proptosis greater than 2 mm.
- Close to 60% of patients reported improvement in diplopia.
- Lumvoa demonstrated a favorable side-effect profile with low rates of adverse events.
- Hearing symptoms were reported in about 5% of patients during the clinical trial.
Clinical Implications
Clinicians should ensure accurate diagnosis of TED through comprehensive clinical examination before initiating treatment with Lumvoa.
Conclusion
The approval of Lumvoa provides a new treatment option for thyroid eye disease.
Related Resources & Content
- Viridian Therapeutics, FDA, 2026 -- New Treatment for TED
- The Ophthalmologist, 2026 -- Phase 3 Win for TED Therapy
- Ophthalmology Management, 2026 -- A New Era of Targeted Treatment for TED
- EUGOGO, 2021 -- Clinical Practice Guidelines for TED
- NEJM, 2020 -- Teprotumumab for the Treatment of Active Thyroid Eye Disease
- ophthalmology management — A New Era of Targeted Treatment for TED
- 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy | European Journal of Endocrinology | Oxford Academic
- Teprotumumab for the Treatment of Active Thyroid Eye Disease | New England Journal of Medicine
- Review
Based on findings from:
New Treatment for TED
The Ophthalmologist, 2026.
https://theophthalmologist.com/issues/2026/articles/august/new-treatment-for-ted/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
